Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.48 |
| ▸ | MCOLN3 | Q8TDD5 | 1/20 | 0.48 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.46 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.40 |
| ▸ | HTT | P42858 | 1/20 | 0.40 |
| ▸ | NR1H2 | P55055 | 6/20 | 0.39 |
| ▸ | NR1H3 | Q13133 | 5/20 | 0.39 |
| ▸ | BCL9 | O00512 | 2/20 | 0.39 |
| ▸ | CTNNB1 | P35222 | 2/20 | 0.39 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.39 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.39 |
| ▸ | AKR1C1 | Q04828 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.38 |
| ▸ | CNR1 | P21554 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1346988 | 0.89 | NR1H2 (0.44) | MAPK1NR1H2NR1H3HSD17B10 | |
| Hydrochloric Acid SCHEMBL1349704 | 0.80 | HTR2C (0.41) | NR1H2NR1H3 | |
| SCHEMBL1347787 | 0.80 | NR1H2 (0.49) | NR1H2NR1H3 | |
| SCHEMBL1349030 | 0.76 | NR1H2 (0.41) | MAPK1NR1H2NR1H3KMT2AHSD17B10 | |
| SCHEMBL1349434 | 0.75 | AKR1C3 (0.44) | NR1H2NR1H3BCL9CTNNB1AKR1C3 | |
| SCHEMBL1349430 | 0.75 | AKR1C3 (0.44) | NR1H2NR1H3BCL9CTNNB1AKR1C3 | |
| SCHEMBL1347181 | 0.75 | AKR1C3 (0.44) | NR1H2NR1H3BCL9CTNNB1AKR1C3 | |
| SCHEMBL1347177 | 0.75 | AKR1C3 (0.44) | NR1H2NR1H3BCL9CTNNB1AKR1C3 | |
| SCHEMBL1347178 | 0.75 | AKR1C3 (0.44) | NR1H2NR1H3BCL9CTNNB1AKR1C3 | |
| SCHEMBL1346809 | 0.73 | ALDH1A1 (0.40) | MAPK1NR1H2NR1H3AKR1C3AKR1C1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2288594-B1 | IMIDAZOLIDINE DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2014-07-02 | — | — | EP | claimed |
| EP-2288594-A1 | IMIDAZOLIDINE DERIVATIVES | F. Hoffmann-La Roche AG (CH) | 2011-03-02 | — | — | EP | claimed |
| US-20090312382-A1 | NOVEL IMIDAZOLIDINE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2009-12-17 | — | — | US | claimed |
| WO-2009150109-A1 | IMIDAZOLIDINE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2009-12-17 | — | — | WO | claimed |
| EP-2288594-B1 | IMIDAZOLIDINE DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2014-07-02 | — | — | EP | disclosed |
| US-8063088-B2 | Imidazolidine derivatives | HOFFMANN-LA ROCHE INC. (US) | 2011-11-22 | — | — | US | disclosed |
| EP-2288594-A1 | IMIDAZOLIDINE DERIVATIVES | F. Hoffmann-La Roche AG (CH) | 2011-03-02 | — | — | EP | disclosed |
| US-20090312382-A1 | NOVEL IMIDAZOLIDINE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2009-12-17 | — | — | US | disclosed |
| WO-2009150109-A1 | IMIDAZOLIDINE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2009-12-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090312382-A1 | NOVEL IMIDAZOLIDINE DERIVATIVES | NR1H2, NR1H3, NR1D2 | LMNA 2179/4885MCOLN3 3824/4885TDP1 3106/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.